Evidence map›Paper›PMID 27854208›Full record

ArticleJournal of neuromuscular diseases2016

Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA.

Mark A Price, Victoria Barghout, Olivier Benveniste, Lisa Christopher-Stine, Alastair Corbett, Marianne de Visser, David Hilton-Jones, John T Kissel, Thomas E Lloyd, Ingrid E Lundberg and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuromuscular diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 62 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Observational
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 7 countries.

Mark A PriceRTI Health Solutions, Research Triangle Park, NC, USA.
Victoria BarghoutVEB HealthCare LLC, Morristown, NJ, USA.
Olivier BenvenisteAssistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Internal Medicine, Pierre and Marie Curie University, Paris, France.
Lisa Christopher-StineJohns Hopkins Myositis Center, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USA.
Alastair CorbettDepartment of Neurology, Concord Hospital, Concord, NSW, Australia.
Marianne de VisserDepartment of Neurology, Academic Medical Center, Amsterdam, Netherlands.
David Hilton-JonesDepartment of Neurology, John Radcliffe Hospital, Oxford, UK.
John T KisselDepartments of Neurology and Pediatrics, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Thomas E LloydDepartments of Neurology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ingrid E LundbergRheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden.
Francis MastagliaInstitute for Immunology and Infectious Diseases, Murdoch University, WA, Australia.
Tahseen MozaffarDepartment of Neurology and Orthopedic Surgery, University of California, Irvine, CA, USA.
Merrilee NeedhamWestern Australian Neuromuscular Research Institute, University of Western Australia, Murdoch University and Department of Neurology, Fiona Stanley Hospital, Perth, WA, Australia.
Jens SchmidtDepartment of Neurology, University Medical Center Göttingen; Department of Neuroimmunology, Institute for Multiple Sclerosis Research and Hertie Foundation, University Medical Center Göttingen, Göttingen, Germany.
Kumaraswamy SivakumarArizona Neurological Research Center, Scottsdale, AZ, USA.
Carla DeMuroRTI Health Solutions, Research Triangle Park, NC, USA.
Brian S TsengNovartis Pharma Corporation, East Hanover, NJ, USA.
Johns Hopkins University · USMurdoch University · AURTI Health Solutions · USAmsterdam UMC Location University of Amsterdam · NLArizona Research Center · USConcord Repatriation General Hospital · AUJohn Radcliffe Hospital · GBKarolinska University Hospital · SENovartis (United States) · USSorbonne Université · FRThe Ohio State University Wexner Medical Center · USUniversitätsmedizin Göttingen · DEUniversity of California, Irvine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is a paucity of data on mortality and causes of death (CoDs) in patients with sporadic inclusion body myositis (sIBM), a rare, progressive, degenerative, inflammatory myopathy that typically affects those aged over 50 years.

objectiveBased on patient records and expertise of clinical specialists, this study used questionnaires to evaluate physicians' views on clinical characteristics of sIBM that may impact on premature mortality and CoDs in these patients.

methodsThirteen physicians from seven countries completed two questionnaires online between December 20, 2012 and January 15, 2013. Responses to the first questionnaire were collated and presented in the second questionnaire to seek elaboration and identify consensus.

resultsAll 13 physicians completed both questionnaires, providing responses based on 585 living and 149 deceased patients under their care. Patients were reported to have experienced dysphagia (60.2%) and injurious falls (44.3%) during their disease. Over half of physicians reported that a subset of their patients with sIBM had a shortened lifespan (8/13), and agreed that bulbar dysfunction/dysphagia/oropharyngeal involvement (12/13), early-onset disease (8/13), severe symptoms (8/13), and falls (7/13) impacted lifespan. Factors related to sIBM were reported as CoDs in 40% of deceased patients. Oropharyngeal muscle dysfunction was ranked as the leading feature of sIBM that could contribute to death. The risk of premature mortality was higher than the age-matched comparison population.

conclusionsIn the absence of data from traditional sources, this study suggests that features of sIBM may contribute to premature mortality and may be used to inform future studies.

Indexed as

Cause of DeathMortality, PrematureAdultAgedAged, 80 and overAustraliaEuropeFemaleHealth SurveysHumansMaleMiddle AgedMyositis, Inclusion BodyPhysiciansUnited Statescause of deathdeglutition disorderinclusion bodymorbiditymortalitymyositisMyositisneuromuscular disease

Identifiers

PMID27854208
PMCPMC5271419
OpenAlexW2334105894

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.